Connor, Clark & Lunn Investment Management (CC&L)
EVFM

Connor, Clark & Lunn Investment Management (CC&L)’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-26,550
Closed -$1.13M – 1183
2020
Q2 		$1.13M Buy
+26,550
New +$1.79M 0.01% 583

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s EVFM Position: Q3 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2020, closing a stake of 26,550 shares — an estimated $1.13M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EVFM in Q2 2020 and held it in 1 quarter. The position peaked at $1.13M in Q2 2020. 99 funds tracked by Wall St. Rank hold EVFM as of Q3 2020.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 26,550 Evofem Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $1.13M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Evofem Biosciences, Inc. Common Stock position peaked at $1.13M in Q2 2020.
  • 99 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2020, filed 12 Nov 2020.